Results 151 to 160 of about 17,625 (252)

Correction: Kubik et al. An Infrared Energy Device for the Treatment of Facial Skin Aging. <i>Biomedicines</i> 2025, <i>13</i>, 2878. [PDF]

open access: yesBiomedicines
Kubik P   +7 more
europepmc   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Comparison of three multiplex immunoassays for biomarker analysis in stratum corneum tape strips. [PDF]

open access: yesSci Rep
Metwally NKA   +6 more
europepmc   +1 more source

The exposomal imprint on rosacea: More than skin deep

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rosacea reflects systemic and environmental interactions, not just a skin disorder. Key factors include environmental triggers, genetic and microbiome influences, diagnostic gaps in skin of colour and social determinants. Advances in multi‐omics and exposome integration highlight pathways towards precision medicine, prevention and equitable, patient ...
Katerina Grafanaki   +3 more
wiley   +1 more source

Rapid and long‐lasting remission of refractory Hailey‐Hailey disease by IL‐13 inhibition with tralokinumab

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Oliver Brandt   +2 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy